Olivia Blazek

Olivia Blazek

Auto-generated profile, based on publicly available information

Olivia Blazek

Heart and Vascular Institute, Department of Medicine, Hartford HealthCare, Hartford, CT, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Hypertension
Verified
Journal Article
Open access
JCJennifer L. Cluett
Jennifer L. Cluett
OBOlivia Blazek
Olivia Blazek
ABAngela L. Brown
Angela L. Brown
CECara East
Cara East
KFKeith C. Ferdinand
Keith C. Ferdinand
ODon behalf of the American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on the Kidney in Cardiovascular Disease; and Council on Peripheral Vascular Disease
on behalf of the American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on the Kidney in Cardiovascular Disease; and Council on Peripheral Vascular Disease
Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the widespread availability of both pharmacological and lifestyle therapeutic options, blood pressure control rates across the globe are worsening. In fact, only 23% of individuals with high blood pressure in the United States achieve treatment goals. In 2023, the US Food and Drug Administration approved renal denervation, a catheter-based procedure that ablates the renal sympathetic nerves, as an adjunctive treatment for patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. This approval followed the publication of multiple randomized clinical studies using rigorous trial designs, all incorporating renal angiogram as the sham control. Most but not all of the new generation of trials reached their primary end point, demonstrating modest efficacy of renal denervation in lowering blood pressure across a spectrum of hypertension, from mild to truly resistant. Individual patient responses vary, and further research is needed to identify those who may benefit most. The initial safety profile appears favorable, and multiple ongoing studies are assessing longer-term efficacy and safety. Multidisciplinary teams that include hypertension specialists and adequately trained proceduralists are crucial to ensure that referrals are made appropriately with full consideration of the potential risks and benefits. Incorporating patient preferences and engaging in shared decision-making conversations will help patients make the best decisions given their individual circumstances. Although further research is clearly needed, renal denervation presents a novel treatment strategy for patients with uncontrolled blood pressure.

4 October 2023 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
GPGregory A. Panza
Gregory A. Panza
OBOlivia Blazek
Olivia Blazek
JTJoseph Tortora
Joseph Tortora
SSStephanie Saucier
Stephanie Saucier
AFAntonio B. Fernandez
Antonio B. Fernandez


8 July 2025 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
SMSean R. McMahon
Sean R. McMahon
ILIna Lico
Ina Lico
EPEtee Patel
Etee Patel
OBOlivia Blazek
Olivia Blazek
WDW. Lane Duvall
W. Lane Duvall